Guildford, Surrey-based Futura Medical, a pharma group that develops products for consumer healthcare, said its erection-enhancing condom CSD500 has been recommended for CE mark approval by the European Union.
CSD500 incorporates an erectogenic compound to help men maintain a firmer erection during intercourse whilst wearing a condom.
The CE mark would enable the condom to be sold in 29 European territories and a number of other non-European countries.
Futura Medical said a majority of men and women who used CSD500 reported longer lasting sexual experience compared to a standard condom, in a company co-sponsored double blind clinical study.
Reckitt Benckiser, makers of the Durex branded condom, has exclusive global rights to CSD500.
Once CSD500 is launched, Futura will receive royalty payments from Reckitt Benckiser based on product sales.